title: Viability of, and basic fibroblast growth factor secretion by, human peritoneal mesothelial cells cultured with various components of peritoneal dialysis fluid.
abstract: In patients on long-term continuous ambulatory peritoneal dialysis (CAPD), peritoneal dysfunction is considered to be due to the loss of peritoneal mesothelial cells and to subsequent peritoneal fibrosis and neovascularization. Our aim in the present study was to clarify the role of various components of peritoneal dialysis fluid in the occurrence of peritoneal dysfunction in CAPD patients. We used a cell counting assay and ELISA to study the viability of human peritoneal mesothelial cells and their secretion of basic fibroblast growth factor (bFGF)--which induces peritoneal fibrosis and neovascularization--by cells cultured with various components of peritoneal dialysis fluid. The viability of cultured cells, ranked from highest to lowest by solution type, was bicarbonate (40 mEq/L) > lactate (15 mEq/L) + bicarbonate (25 mEq/L) > lactate (40 mEq/L). Viability also showed a concentration-dependent decrease in the presence of advanced glycation end-products of bovine serum albumin. The bFGF level in the supernatant showed a concentration-dependent increase in the presence of glucose and glycated albumin; bFGF level decreased as the bicarbonate concentration increased. Low levels of glucose, lactate, and glycated albumin, and a high concentration of bicarbonate may preserve the viability of peritoneal mesothelial cells and prevent bFGF secretion.
authors.affiliation: Department of Internal Medicine, National Kure Medical Center, Kure, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ogata
authors.forename: Noriaki
authors.initials: N
authors.lastname: Yorioka
authors.forename: Kei
authors.initials: K
authors.lastname: Kiribayashi
authors.forename: Takayuki
authors.initials: T
authors.lastname: Naito
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kuratsune
authors.forename: Yoji
authors.initials: Y
authors.lastname: Nishida
mesh_terms: D001639:Bicarbonates / Q000494:pharmacology; D002470:Cell Survival; D002478:Cells, Cultured; D003470:Culture Media; D015314:Dialysis Solutions / Q000737:chemistry / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D004847:Epithelial Cells / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism*; D005947:Glucose / Q000494:pharmacology; D017127:Glycation End Products, Advanced / Q000494:pharmacology; D006801:Humans; D019344:Lactic Acid / Q000494:pharmacology; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010537:Peritoneum / Q000166:cytology* / Q000378:metabolism*; D012710:Serum Albumin, Bovine / Q000494:pharmacology
chemical_list: D001639:Bicarbonates; D003470:Culture Media; D015314:Dialysis Solutions; D017127:Glycation End Products, Advanced; C081628:advanced glycation end products-bovine serum albumin; D016222:Fibroblast Growth Factor 2; D012710:Serum Albumin, Bovine; D019344:Lactic Acid; D005947:Glucose